Skip to content

Cataract — Overview

TL;DR — Cataract is opacification of the crystalline lens; it is the single largest cause of blindness in the world and the only established treatment is to remove the lens and replace it with an intraocular lens (IOL) (Lam 2015, PMID 27188414). In 2020 cataract caused an estimated 15.2 million cases of blindness (95% UI 12.7–18.0) and 78.8 million cases of moderate-or-severe vision impairment (67.2–91.4) in adults aged ≥50 years (GBD Vision Loss Expert Group 2021, PMID 33275949); on an all-ages, cataract-specific model the counts are 17.0 million blind (39.6% of all blindness) and 83.5 million with MSVI (28.3%), 60% and 59% of them women (Vision Loss Expert Group 2024, PMID 38461217). The operation itself is highly effective and among the most cost-effective in medicine (US$9–$1,600 per QALY in developing countries, $245–$22,000 in Western countries) (Lansingh 2007, PMID 17383730) — so the field's central problem is not whether surgery works but whether it reaches people, and whether what they get back is the vision they value. Two structural facts organise everything else: age-standardised cataract blindness fell 27.5% between 1990 and 2020 while the absolute number of cataract-blind people rose 29.7%, because ageing and population growth outran surgical capacity (PMID 38461217); and visual acuity is a poor proxy for cataract disability, so acuity-only indications and acuity-only outcome reporting both systematically mismeasure the disease (Steinberg 1994, PMID 8185520; See 2019, PMID 30489358).

What cataract is

The transparent human lens holds cytoplasmic protein at concentrations up to ~900 mg/mL in organelle-free fibre cells; that ordered crystallin packing, plus a low-oxygen environment and a powerful antioxidant system, is what keeps light scatter low (Muranov 2022, PMID 35508906). Cataract is the loss of that order. It is not one lesion: nuclear, cortical and posterior subcapsular (PSC) opacities have different anatomy, different risk-factor profiles, different symptom patterns and different rates of progression, and mixed forms are common — in the Blue Mountains Eye Study 22% of people who developed any cataract developed more than one type (Kanthan 2008, PMID 17900695). The taxonomy and its measurement problems are in classification and grading; the molecular story is in lens biology and pathogenesis. The field's framing has been stable for two decades: a 2005 seminar already identified age, genetic composition, ultraviolet exposure and diabetes as the risk factors, noted that no method of halting cataract formation had been shown effective, and predicted that cataract would grow in public-health importance as populations aged (Asbell 2005, PMID 15708105).

The operative definition used in epidemiology and in the clinic is different again. Population surveys count cataract blindness or cataract vision impairment at a presenting-acuity threshold; clinics count visually significant cataract — a lens opacity judged to explain a patient's functional loss. These are not interchangeable, and the choice of threshold moves prevalence, coverage and outcome statistics substantially (epidemiology and global burden).

Why a curable opacity is still the leading cause of blindness

Quantity Value Population / year Source
Cataract blindness 15.2 million (12.7–18.0) Adults ≥50, 2020 GBD 2019 VLEG, PMID 33275949
Cataract MSVI 78.8 million (67.2–91.4) Adults ≥50, 2020 PMID 33275949
Cataract blindness (all ages) 17.0 million; 39.6% of all blindness 2020 PMID 38461217
Change in cataract-blind count +29.7% 1990–2020 PMID 38461217
Change in age-standardised cataract blindness prevalence −27.5% 1990–2020 PMID 38461217
Female share of cataract blindness / MSVI 60% / 59% 2020 PMID 38461217
All-cause blindness projection 61.0 million (52.9–69.3) 2050 PMID 33275950
Median effective cataract surgical coverage ranges 3.8% (Guinea-Bissau 2010) to 70.3% (Hungary 2015) 148 RAAB surveys, 55 countries McCormick 2022, PMID 36240806

The World Health Assembly's Global Action Plan target — a 25% reduction from 2010 to 2019 in avoidable vision impairment (cataract plus uncorrected refractive error) — was not met: crude prevalence of avoidable vision impairment in adults ≥50 did not change (−0.2%, 95% UI −1.5 to 1.0), and although age-standardised avoidable blindness fell 15.4% (−16.8 to −14.3), case counts rose 10.8% for blindness and 31.5% for MSVI (PMID 33275949). In 2021 the 74th World Health Assembly replaced it with a target of a 30-percentage-point increase in effective cataract surgical coverage (eCSC) by 2030 (Keel 2021, PMID 34237266) — an indicator that, unlike a raw surgical rate, only counts an operation if the visual outcome was good. Baseline eCSC estimates from 148 population surveys in 55 countries show both the level and the quality gap between coverage and effective coverage (PMID 36240806). Details in access, equity and service delivery.

Surgery: what it does and does not fix

Modern surgery removes the lens through a 2–3 mm incision by phacoemulsification, or through a slightly larger sutureless tunnel by manual small-incision cataract surgery (MSICS), and implants a posterior-chamber IOL in the capsular bag. In a randomised comparison of the two in 200 eyes, endothelial cell loss at six weeks did not differ (543 vs 506 cells/mm² by manual count, P = 0.44) and corrected acuity was 6/18 or better in 98.5% vs 97.3% (Gogate 2010, PMID 20152605) — which is why MSICS remains the appropriate high-volume technique wherever phaco equipment and consumables are limiting (Winterton 2026, PMID 41175388). Femtosecond-laser assistance automates capsulotomy and lens fragmentation but did not improve the outcomes patients experience: in the 785-patient FACT trial the 3-month unaided-acuity difference was −0.01 logMAR (95% CI −0.05 to 0.03), and 71% of both arms were within ±0.5 D of target (Day 2020, PMID 32386810); in the 907-patient FEMCAT superiority trial the composite success rate was 41.1% with laser vs 43.6% with phaco (adjusted OR 0.85, 95% CI 0.64–1.12, p = 0.250), with an incremental €10,703 saved per additional success using conventional phaco (Schweitzer 2020, PMID 31954466). See surgical technique.

What surgery reliably restores is optical clarity. What it does not guarantee is the refractive result (the patient's spectacle dependence and residual astigmatism — see IOL power calculation), freedom from photic phenomena (see intraocular lenses), or benefit in an eye whose retina or optic nerve is also diseased (see surgery with coexisting eye disease). In the UK Cataract National Dataset of 55,567 operations, the adverse indicators for acuity outcome were age, short axial length, any ocular comorbidity, AMD, diabetic retinopathy, amblyopia, corneal pathology, previous vitrectomy — and posterior capsule rupture, the only modifiable one, which carried an odds ratio of 5.74 for acuity loss (Sparrow 2012, PMID 22441022).

The four numbers that define surgical safety

Complication Frequency Source
Posterior capsule rupture 1.1% of 2,853,376 EUREQUO surgeries (annual range 0.60–1.65%, declining) Segers 2022, PMID 34074994
Dropped nucleus 0.071% of 1,715,348 EUREQUO surgeries Lundström 2020, PMID 32126043
Endophthalmitis 4,502/6,809,732 eyes (0.066%) pooled; 29/16,603 in the ESCRS randomised trial Kato 2022, PMID 36258003; ESCRS Endophthalmitis Study Group 2007, PMID 17531690
Pseudophakic retinal detachment 36,886/5,480,448 (0.66 per 100 patients, 95% CI 0.43–1.00) Alshammari 2024, PMID 39172224

Omitting intracameral cefuroxime raised endophthalmitis risk 4.92-fold (95% CI 1.87–12.9) in the only large randomised prophylaxis trial (PMID 17531690); the subsequent 6.8-million-eye network meta-analysis found that only the intracameral route significantly reduced risk (OR 0.19, 99.4% CI 0.12–0.30), with agent-level rankings resting largely on observational data (PMID 36258003). Full treatment in complications and red flags and safety concerns.

The most common late complication is not an injury but a biological one: residual lens epithelial cells re-colonise the posterior capsule. Pooled incidence of posterior capsule opacification was 11.8% at 1 year, 20.7% at 3 years and 28.4% at 5 years in the pre-sharp-edge era (Schaumberg 1998, PMID 9663224); sharp optic edges cut Nd:YAG capsulotomy substantially by three years (RR 0.21, 95% CI 0.11–0.41) (Maedel 2021, PMID 34398965). See posterior capsule opacification.

Acuity is the wrong single outcome

Cataract's defining measurement problem is that Snellen acuity in a dark lane under-detects the disability people actually report. The VF-14 functional index correlated better with patients' own rating of trouble with vision than any measure of acuity did, and was about three times more responsive to surgery than a generic health-status instrument (effect size ~1.00 vs 0.30) (Steinberg 1994, PMID 8185520; Cassard 1995, PMID 7487617). Rasch-scaled short instruments — Catquest-9SF and Cat-PROM5 — now carry that logic into routine services with person reliability 0.88–0.90 and standardised responsiveness ~1.45–1.47 SD (Lundström 2009, PMID 19251145; Sparrow 2018, PMID 29386619). Outcome domains that move independently of each other — acuity, refractive prediction error, contrast, reading, patient-reported function, complications — are enumerated in (Qin 2018, PMID 28937505) and treated in outcomes and quality of life.

The functional consequences are measurable outside the eye. In an Australian cohort of 409 people aged ≥65 awaiting bilateral surgery, the age- and sex-adjusted fall rate was 1.17 per year (95% CI 0.95–1.43) before surgery and 0.81 (0.63–1.04) after first-eye surgery (Keay 2022, PMID 35702892). A randomised trial of expedited versus 12-month-delayed second-eye surgery in 239 women over 70 found improved visual disability, confidence and general health status but a non-significant 32% reduction in fall rate (rate ratio 0.68, 95% CI 0.39–1.19, P = 0.18) (Foss 2006, PMID 16364936) — an honest illustration that first-eye and second-eye benefits are not the same claim.

No drug reverses cataract

Attempts at pharmacological prevention have repeatedly failed at the level that matters. The Age-Related Eye Disease Study randomised 4,757 participants to high-dose vitamin C, vitamin E and beta-carotene and found no effect on lens-opacity progression or on cataract surgery (AREDS Research Group 2001, PMID 11594943). A Cochrane review of N-acetylcarnosine drops found no reliable evidence of benefit (Dubois 2017, PMID 28245346). Lanosterol reversed crystallin aggregation in vitro and in animal lenses and identified LSS mutations in congenital cataract families (Zhao 2015, PMID 26200341), but no human trial has established that any topical agent clears an established human cataract. Observational nutritional associations (for example pooled RR 0.73, 95% CI 0.58–0.92 for higher dietary vitamin E) are consistent with confounding by general health behaviour and have not been converted into randomised benefit (Zhang 2015, PMID 25591715). See non-surgical and preventive approaches.

Genuine prevention levers are therefore behavioural and environmental. Smoking shows a dose–response relationship with cataract extraction, and risk falls after cessation but takes ~20 years to approach never-smoker levels in heavy smokers (Lindblad 2005, PMID 15961589). Cumulative UV-B exposure raised cortical (but not nuclear) cataract risk in the Chesapeake Bay watermen study — a doubling of cumulative exposure carried OR 1.60 (95% CI 1.01–2.64) (Taylor 1988, PMID 3185661). See risk factors.

Children are a separate disease

Congenital and infantile cataract is rare but consumes a disproportionate share of lifetime visual disability because it competes with the critical period for visual development. The Infant Aphakia Treatment Study randomised 114 infants operated at 1–6 months to primary IOL or aphakia with contact lens: at 10.5 years the median treated-eye acuity was 0.89 vs 0.86 logMAR (P = 0.82), 25% achieved ≤0.30 logMAR and 44% were ≥1.00 logMAR in both arms — but adverse events (81% vs 56%, P = 0.008) and additional intraocular surgeries (72% vs 16%, P < 0.0001) were far commoner with a primary IOL (Lambert 2020, PMID 32077909; Plager 2014, PMID 25077835). Glaucoma or glaucoma suspect affected 41% of the cohort by 10.5 years (Wong 2026, PMID 41419074). Adult evidence must never be transferred here. See congenital and paediatric cataract.

Map of this knowledge base

Foundations: classification and grading, epidemiology and global burden, lens biology and pathogenesis, risk factors. Non-age-related disease: congenital and paediatric cataract, secondary and traumatic cataract. The surgical pathway in order: diagnosis and preoperative assessment → IOL power calculation → intraocular lenses → anaesthesia and perioperative care → surgical technique → complications → posterior capsule opacification. Harder cases: surgery with coexisting eye disease. What the operation is for: outcomes and quality of life, patient experience and advocacy. Systems and evidence: access, equity and service delivery, guidelines, clinical trials landscape, non-surgical and preventive approaches, red flags and safety concerns.

Open questions

  • Does raising effective coverage cost quality? eCSC is designed to make volume and outcome one number (PMID 34237266), but no study has followed a national scale-up prospectively while measuring risk-adjusted PCR, endophthalmitis and patient-reported outcomes, so the trade-off between throughput and quality remains asserted rather than measured (PMID 36240806).
  • Can a function-based indication be operationalised fairly? Acuity is a demonstrably poor gauge of cataract disability (PMID 8185520; PMID 30489358) and validated Rasch PROMs now exist (PMID 29386619), but no health system has published a prospective evaluation of a PROM-based referral rule against an acuity threshold for equity of access and outcome.
  • Is there any pharmacological target with human proof of engagement? Aggregation-reversing chemistry is established in vitro (PMID 26200341) and antioxidant supplementation has failed in a 4,757-participant randomised trial (PMID 11594943); the missing step is a human biomarker showing that a drug altered lens protein state rather than transient optical properties.
  • Why do women carry 60% of cataract blindness? The sex disparity is quantified globally (PMID 38461217) and appears in surgical access for girls with bilateral cataract in low-income settings (Gilbert 2016, PMID 26992842), but the causal decomposition between longevity, incidence and access has not been done.

References

  1. Lam D, Rao SK, Ratra V, et al. Cataract. Nature reviews. Disease primers. 2015;1:15014. PMID 27188414
  2. GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. The Lancet. Global health. 2021;9:e144-e160. PMID 33275949
  3. Vision Loss Expert Group of the Global Burden of Disease Study, GBD 2019 Blindness and Vision Impairment Collaborators. Global estimates on the number of people blind or visually impaired by cataract: a meta-analysis from 2000 to 2020. Eye (London, England). 2024;38:2156-2172. PMID 38461217
  4. Lansingh VC, Carter MJ, Martens M. Global cost-effectiveness of cataract surgery. Ophthalmology. 2007;114:1670-8. PMID 17383730
  5. Steinberg EP, Tielsch JM, Schein OD, et al. The VF-14. An index of functional impairment in patients with cataract. Archives of ophthalmology (Chicago, Ill. : 1960). 1994;112:630-8. PMID 8185520
  6. See CW, Iftikhar M, Woreta FA. Preoperative evaluation for cataract surgery. Current opinion in ophthalmology. 2019;30:3-8. PMID 30489358
  7. Muranov KO, Ostrovsky MA. Biochemistry of Eye Lens in the Norm and in Cataractogenesis. Biochemistry. Biokhimiia. 2022;87:106-120. PMID 35508906
  8. Kanthan GL, Wang JJ, Rochtchina E, et al. Ten-year incidence of age-related cataract and cataract surgery in an older Australian population. The Blue Mountains Eye Study. Ophthalmology. 2008;115:808-814.e1. PMID 17900695
  9. Asbell PA, Dualan I, Mindel J, et al. Age-related cataract. Lancet (London, England). 2005;365:599-609. PMID 15708105
  10. GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. The Lancet. Global health. 2021;9:e130-e143. PMID 33275950
  11. McCormick I, Butcher R, Evans JR, et al. Effective cataract surgical coverage in adults aged 50 years and older: estimates from population-based surveys in 55 countries. The Lancet. Global health. 2022;10:e1744-e1753. PMID 36240806
  12. Keel S, Müller A, Block S, et al. Keeping an eye on eye care: monitoring progress towards effective coverage. The Lancet. Global health. 2021;9:e1460-e1464. PMID 34237266
  13. Gogate P, Ambardekar P, Kulkarni S, et al. Comparison of endothelial cell loss after cataract surgery: phacoemulsification versus manual small-incision cataract surgery: six-week results of a randomized control trial. Journal of cataract and refractive surgery. 2010;36:247-53. PMID 20152605
  14. Winterton C, Mai A, Pettey J. Manual small incision cataract surgery. Current opinion in ophthalmology. 2026;37:31-35. PMID 41175388
  15. Day AC, Burr JM, Bennett K, et al. Femtosecond Laser-Assisted Cataract Surgery Versus Phacoemulsification Cataract Surgery (FACT): A Randomized Noninferiority Trial. Ophthalmology. 2020;127:1012-1019. PMID 32386810
  16. Schweitzer C, Brezin A, Cochener B, et al. Femtosecond laser-assisted versus phacoemulsification cataract surgery (FEMCAT): a multicentre participant-masked randomised superiority and cost-effectiveness trial. Lancet (London, England). 2020;395:212-224. PMID 31954466
  17. Sparrow JM, Taylor H, Qureshi K, et al. The Cataract National Dataset electronic multi-centre audit of 55,567 operations: risk indicators for monocular visual acuity outcomes. Eye (London, England). 2012;26:821-6. PMID 22441022
  18. Segers MHM, Behndig A, van den Biggelaar FJHM, et al. Risk factors for posterior capsule rupture in cataract surgery as reflected in the European Registry of Quality Outcomes for Cataract and Refractive Surgery. Journal of cataract and refractive surgery. 2022;48:51-55. PMID 34074994
  19. Lundström M, Dickman M, Henry Y, et al. Risk factors for dropped nucleus in cataract surgery as reflected by the European Registry of Quality Outcomes for Cataract and Refractive Surgery. Journal of cataract and refractive surgery. 2020;46:287-292. PMID 32126043
  20. Kato A, Horita N, Namkoong H, et al. Prophylactic antibiotics for postcataract surgery endophthalmitis: a systematic review and network meta-analysis of 6.8 million eyes. Scientific reports. 2022;12:17416. PMID 36258003
  21. Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. Journal of cataract and refractive surgery. 2007;33:978-88. PMID 17531690
  22. Alshammari AJ, Alqam RA, Aldeej MA, et al. Retinal Detachment Following Cataract Surgery: A Systematic Review and Meta-analysis of Incidence, Preoperative Risk Factors, and Postoperative Complications. Ophthalmic surgery, lasers & imaging retina. 2024;55:668-674. PMID 39172224
  23. Schaumberg DA, Dana MR, Christen WG, et al. A systematic overview of the incidence of posterior capsule opacification. Ophthalmology. 1998;105:1213-21. PMID 9663224
  24. Maedel S, Evans JR, Harrer-Seely A, et al. Intraocular lens optic edge design for the prevention of posterior capsule opacification after cataract surgery. The Cochrane database of systematic reviews. 2021;8:CD012516. PMID 34398965
  25. Cassard SD, Patrick DL, Damiano AM, et al. Reproducibility and responsiveness of the VF-14. An index of functional impairment in patients with cataracts. Archives of ophthalmology (Chicago, Ill. : 1960). 1995;113:1508-13. PMID 7487617
  26. Lundström M, Pesudovs K. Catquest-9SF patient outcomes questionnaire: nine-item short-form Rasch-scaled revision of the Catquest questionnaire. Journal of cataract and refractive surgery. 2009;35:504-13. PMID 19251145
  27. Sparrow JM, Grzeda MT, Frost NA, et al. Cataract surgery patient-reported outcome measures: a head-to-head comparison of the psychometric performance and patient acceptability of the Cat-PROM5 and Catquest-9SF self-report questionnaires. Eye (London, England). 2018;32:788-795. PMID 29386619
  28. Qin VL, Conti FF, Singh RP. Measuring outcomes in cataract surgery. Current opinion in ophthalmology. 2018;29:100-104. PMID 28937505
  29. Keay L, Ho KC, Rogers K, et al. The incidence of falls after first and second eye cataract surgery: a longitudinal cohort study. The Medical journal of Australia. 2022;217:94-99. PMID 35702892
  30. Foss AJ, Harwood RH, Osborn F, et al. Falls and health status in elderly women following second eye cataract surgery: a randomised controlled trial. Age and ageing. 2006;35:66-71. PMID 16364936
  31. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Archives of ophthalmology (Chicago, Ill. : 1960). 2001;119:1439-52. PMID 11594943
  32. Dubois VD, Bastawrous A. N-acetylcarnosine (NAC) drops for age-related cataract. The Cochrane database of systematic reviews. 2017;2:CD009493. PMID 28245346
  33. Zhao L, Chen XJ, Zhu J, et al. Lanosterol reverses protein aggregation in cataracts. Nature. 2015;523:607-11. PMID 26200341
  34. Zhang Y, Jiang W, Xie Z, et al. Vitamin E and risk of age-related cataract: a meta-analysis. Public health nutrition. 2015;18:2804-14. PMID 25591715
  35. Lindblad BE, Håkansson N, Svensson H, et al. Intensity of smoking and smoking cessation in relation to risk of cataract extraction: a prospective study of women. American journal of epidemiology. 2005;162:73-9. PMID 15961589
  36. Taylor HR, West SK, Rosenthal FS, et al. Effect of ultraviolet radiation on cataract formation. The New England journal of medicine. 1988;319:1429-33. PMID 3185661
  37. Lambert SR, Cotsonis G, DuBois L, et al. Long-term Effect of Intraocular Lens vs Contact Lens Correction on Visual Acuity After Cataract Surgery During Infancy: A Randomized Clinical Trial. JAMA ophthalmology. 2020;138:365-372. PMID 32077909
  38. Plager DA, Lynn MJ, Buckley EG, et al. Complications in the first 5 years following cataract surgery in infants with and without intraocular lens implantation in the Infant Aphakia Treatment Study. American journal of ophthalmology. 2014;158:892-8. PMID 25077835
  39. Wong C, Das U, Forbes H, et al. Predicting 10 Year Glaucoma Using Anterior Segment Biometry for Infants with Unilateral Congenital Cataract. American journal of ophthalmology. 2026;283:207-213. PMID 41419074
  40. Gilbert CE, Lepvrier-Chomette N. Gender Inequalities in Surgery for Bilateral Cataract among Children in Low-Income Countries: A Systematic Review. Ophthalmology. 2016;123:1245-51. PMID 26992842